RE: 2m bought at 0.95p17 Jun 2026 10:52
Matthew Walls, Chief Executive Officer of GENinCode Plc said: "We continue to strengthen our commercial position supported by the progress of our Thermo Fisher collaboration in the US and EU and the recent US ACC/AHA guideline changes which have increased visibility of our testing and established Polygenic Risk Scores as a new 'risk enhancer' for the prevention of heart disease. Discussions have progressed with the FDA and we anticipate filing our updated De Novo PMA submission in Q3.2026. We have a busy period ahead and anticipate continued growth and commercial updates which we will advise in due course. With a strengthened balance sheet following our Β£4.7 million fundraise, growing commercial traction and continued progress towards our FDA submission, we believe we are well positioned to accelerate growth and deliver on our strategic objectives
1 RNS and this will do 50% from this range!!